RBP4

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Retrieved on: 
Lundi, mai 6, 2024
Stargardt disease, MB BS, Geographic atrophy, FACS, Royal College of Ophthalmologists, MB, Therapy, Retina, Bachelor of Science, Eye, Research fellow, Macular degeneration, RBP4, Moorfields Eye Hospital, ARVO

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a Key Opinion Leader Webinar hosted by Jennifer Kim, Director, Equity Research, of Cantor Fitzgerald on Monday, May 13, 2024, at 2:00 p.m. ET.

Key Points: 
  • Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m.
  • The event will feature Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS (University College London Institute of Ophthalmology and Moorfields Eye Hospital), who will discuss an overview of the unmet need for treatments in Stargardt disease (STGD1) and Geographic Atrophy (GA).
  • Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1.
  • A replay of the webinar will be available approximately one week after the event for 90 days under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events .

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Mardi, mars 12, 2024
ODD, Retina, Stargardt disease, Research, Conference, Vitamin A, Exercise, RPD, Eye, Patient, RBP4, Tissue, ARVO, ATM, Safety, Paratriathlon, Therapy, Macular degeneration, Blood, FDA, DRAGON, Food, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its audited financial results for full-year 2023 and the unaudited and unreviewed financial results for the quarter ended December 31, 2023, and provided a business update.
  • The decrease resulted primarily from higher R&D expenses in the fourth quarter of 2022 as the DRAGON trial reached certain milestones in such quarter.
  • Belite Bio will host a webcast on Tuesday, March 12, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
  • A replay will be available for approximately 90 days following the event at the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events .

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Mardi, novembre 14, 2023
Stargardt disease, Visual acuity, Retina, QEF, Patient, PFIC, Therapy, Conference, Paratriathlon, Grade, Webcast, FAF, Safety, Food, ODD, RPD, Blood, RBP4, Eye, Adolescence, Exercise, Tissue, Vitamin A, University, AMD, DRAGON, Research, Ageing, Disease, FDA, Conference call, Westmead, Geographic atrophy, HIV disease progression rates, Pharmaceutical industry, Fine chemical, Citrus, Security (finance), Cryptocurrency, Stargardt, Hong Kong, PHOENIX, Ophthalmology

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the three-months ended September 30, 2023, and provided a general business update.
  • “We made meaningful progress in the quarter advancing our clinical trials for Tinlarebant and are excited by our results,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.
  • Third Quarter 2023 Financial Results:
    Cash: As of September 30, 2023, the Company had $54.5 million in cash.
  • Belite Bio will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Mercredi, août 9, 2023
Stargardt disease, Hosting, Vitamin A, Patient, RPD, DAF, Ageing, University of Basel, Tissue, ARVO, Cash, University, Therapy, Food, Research, GA, Conference call, FDA, Conference, Safety, Retina, ODD, Eye, RBP4, Stargardt, Paratriathlon, Blood, Adolescence, KOL, AMD, Association for Research in Vision and Ophthalmology, United Kingdom, Pivotal, Fenretinide, Visual acuity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DRAGON, Pharmaceutical industry, Fine chemical, Citrus, Ophthalmology, PHOENIX

ET

Key Points: 
  • ET
    SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced its financial results for the three months ended June 30, 2023 and provided a general business update.
  • Stargardt disease (STGD1): Accumulation of cytotoxic bisretinoids has been implicated in the onset and progression of STGD1.
  • For the three months ended June 30, 2023, general and administration expenses were $1.4 million compared to $0.9 million for the same period in 2022.
  • Belite Bio will host a webcast to discuss the Company’s financial results and provide a business update.

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Retrieved on: 
Lundi, juillet 24, 2023
Therapy, Stargardt disease, Principal investigator, RBP4, Geographic atrophy, GA, Moorfields Eye Hospital, Phase 3, HIV disease progression rates, Patient, SAN, Pleasure, Adolescence, United Kingdom, FDA, DRAGON, Safety, Pharmaceutical industry, PHOENIX

Tinlarebant is an oral, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.

Key Points: 
  • Tinlarebant is an oral, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.
  • “Completing enrollment of all 90 adolescent subjects across 11 countries worldwide in the Phase 3 DRAGON trial marks an important milestone for our late-stage program in STGD1.
  • Topline data for Tinlarebant in the Phase 2 STGD1 study is expected in the fourth quarter of 2023 and the interim data for the Phase 3 DRAGON trial is expected by mid-2024.
  • In addition, Belite plans to have the first patient enrolled in the 2-year Phase 3 study (PHOENIX) of Tinlarebant in Geographic Atrophy (GA) in the third quarter of 2023.

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Jeudi, mai 11, 2023
Insurance, Stargardt disease, Hosting, Vitamin A, Patient, RPD, DAF, University of Basel, Tissue, ARVO, Cash, University, Therapy, Food, Research, GA, Conference call, Paratriathlon, FDA, UCL Institute of Ophthalmology, Conference, Safety, Retina, ODD, Eye, RBP4, Stargardt, Blood, Adolescence, KOL, AMD, Phase 10, United Kingdom, Pivotal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DRAGON, Pharmaceutical industry, Dairy, Fine chemical, Citrus, Cryptocurrency, Ophthalmology, PHOENIX

ET

Key Points: 
  • ET
    SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced its financial results for the first quarter ended March 31, 2023 and provided a general business update.
  • “We remain focused on advancing late-stage development of Tinlarebant and are pleased with the 60% enrollment seen to date in our pivotal Phase 3 DRAGON trial.
  • Among the minority subjects who did transition to DDAF lesions, Tinlarebant slowed the rate of progression compared to those reported in a natural history study.
  • Belite Bio will host a webcast to discuss the Company’s financial results and provide a business update.

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

Retrieved on: 
Jeudi, mai 4, 2023
Therapy, MB, Stargardt disease, UCL Institute of Ophthalmology, RBP4, Stargardt, Bachelor of Science, Belite, Moorfields Eye Hospital, Royal College of Ophthalmologists, Patient, MB BS, Adolescence, FACS, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced it will host a virtual Key Opinion Leader event on focusing on adolescent patients with Stargardt disease (STGD1) on Wednesday, May 10, 2023 at 1:00 PM Eastern Time.

Key Points: 
  • The event will feature Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS (Moorfields Eye Hospital and UCL Institute of Ophthalmology) who will discuss progression of childhood-onset STGD1 and Belite Bio’s Phase 2 study evaluating the safety and efficacy of Tinlarebant (LBS-008) in adolescent STGD1 patients.
  • Tinlarebant (LBS-008) is an oral, once daily RBP4 antagonist designed to reduce the accumulation of ocular vitamin-A based toxins which have been implicated in the onset and progression of STGD1.
  • Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S. and Europe for the treatment of STGD1.
  • A live question and answer session will follow the formal presentations.

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Retrieved on: 
Mardi, avril 11, 2023
Stem cell, IOB, University, Johns Hopkins Hospital, Wilmer Ophthalmological Institute, Stargardt disease, Johns Hopkins School of Medicine, Geographic atrophy, RBP4, Vitamin A, Retina, Belite, Medical school, Moorfields Eye Hospital, Professor, Principal, University of Basel, Society, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, April 11, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical need, today announced it will host a virtual key opinion leader (KOL) event to discuss the RBP4 antagonist tinlarebant and its relevance in the treatment of Stargardt Disease 1.

Key Points: 
  • (Chairman of the Department of Ophthalmology, University of Basel) who will discuss the 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant (LBS-008) for the treatment of Stargardt disease (STGD1).
  • Tinlarebant has been granted Fast Track and Rare Pediatric Disease designations in the U.S., and orphan drug designation in the U.S. and Europe for STGD1.
  • He completed residency at Tübingen’s University Eye Hospital prior to a fellowship at Moorfields Eye Hospital & Institute of Ophthalmology in London.
  • A replay will be available approximately two hours after the event for 90 days.

Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

Retrieved on: 
Samedi, avril 1, 2023
Retina, ARVO, Cash, General Services Administration, D&O, Stargardt disease, ODD, Eye, RBP4, Geographic atrophy, Vitamin A, Dry, Research, Paratriathlon, Administration, Patient, SAN, Blood, Annual general meeting, RPD, Adolescence, DRAGON, United Kingdom, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, D, Pharmaceutical industry, Nursing, Citrus, Cryptocurrency, PHOENIX, Stargardt, Ophthalmology

Stargardt disease (STGD1): Accumulation of cytotoxic bisretinoids has been implicated in the onset and progression of STGD1.

Key Points: 
  • Stargardt disease (STGD1): Accumulation of cytotoxic bisretinoids has been implicated in the onset and progression of STGD1.
  • Belite Bio (NASDAQ: BLTE) became listed on Nasdaq and raised net proceeds of approximately $38.0 million including the overallotment.
  • Full Year 2022 Financial Results:
    Cash and Cash Equivalents: As of December 31, 2022, the Company had $42.1 million in cash.
  • Belite Bio will host a webcast to discuss the Company’s financial results and provide a business update.

Stargardt Disease Drug Pipeline Research Report 2022: Insights on 18+ Xompanies and 20+ Pipeline Drugs - Therapeutic Assessments by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Mercredi, décembre 14, 2022
Health, Biotechnology, Therapy, NDA, Route, RPE, Triglyceride, Lipoprotein, Administration, News, Clinical trial, Route of administration, Eye, Tissue, STRA6, Discovery, RBP4, Vitamin A, Acquisition, Medical device, Pharmaceutical industry, Stargardt disease

This "Stargardt disease Pipeline Insight, 2022" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Stargardt disease pipeline landscape.

Key Points: 
  • This "Stargardt disease Pipeline Insight, 2022" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Stargardt disease pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The assessment part of the report embraces, in depth Stargardt disease commercial assessment and clinical assessment of the pipeline products under development.
  • Stargardt disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.